AivoCode

AivoCode is pioneering precision therapies for neurological and ophthalmic diseases by utilizing molecular "zip codes" to deliver treatments to specific brain regions or cell types. Their groundbreaking discoveries include novel probes for early detection of Alzheimer's disease, a targeted therapeutic platform for traumatic brain injuries, and an innovative intravitreal therapeutic designed to prevent subretinal fibrosis in wet age-related macular degeneration (AMD) patients. Their lead compound, AC01, is a peptide designed to repair the damaged blood-brain barrier, a critical step in mitigating the secondary damage that often follows TBI. Preclinical studies have demonstrated AC01's efficacy in reducing brain lesion size and improving motor function, suggesting its potential to significantly enhance recovery and long-term outcomes for TBI patients.

Jobs: